Whitney Boling, MD
Ophthalmology · Elkhart, INNPI 1629333133
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.9% of the total across 135 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 17.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,249, 2.3 times the $552 reported in 2019.
Across 135 payments — averaging $35.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$836
- Mallinckrodt Hospital Products Inc.$799
- Glaukos Corporation$424
- Amgen$352
- Johnson & Johnson Surgical Vision, Inc.$317
- Genentech USA, Inc.$225
- plus $2K from 21 others
What the payments were for
- Food & beverage$4,55294%
- Education$2946%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 17 | $836 |
| Mallinckrodt Hospital Products Inc. | 21 | $799 |
| Glaukos Corporation | 9 | $424 |
| Amgen(2 entities) | 11 | $352 |
| Johnson & Johnson Surgical Vision, Inc. | 8 | $317 |
| Genentech USA, Inc. | 8 | $225 |
| Sight Sciences, Inc. | 2 | $216 |
| Dompe US, Inc. | 8 | $200 |
| Apellis Pharmaceuticals, Inc. | 4 | $185 |
| AbbVie(2 entities) | 10 | $173 |
| Regeneron Healthcare Solutions, Inc. | 6 | $154 |
| Sun Pharmaceutical Industries Inc. | 2 | $145 |
| Ocular Therapeutix, Inc. | 2 | $140 |
| Kala Pharmaceuticals, Inc. | 1 | $122 |
| Biotissue Holdings Inc. | 6 | $85 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $79 |
| Staar Surgical Company | 1 | $77 |
| Tarsus Pharmaceuticals, Inc. | 3 | $70 |
| Surgical Specialties Corporation (US), Inc. (dba Corza Medical) | 3 | $54 |
| Bausch & Lomb Americas Inc. | 3 | $53 |
| Oyster Point Pharma, Inc. | 2 | $29 |
| Rayner Intraocular Lenses Limited | 1 | $24 |
| Harrow Eye, LLC | 1 | $22 |
| NEW World Medical,inc. | 2 | $21 |
| Ziemer USA | 1 | $17 |
| Romark Laboratories, LC | 1 | $16 |
| Novartis | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,846 in reported general payments places this provider in the 80th percentile of 266 ophthalmology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 18 | $907,704 |
| ActharCorticotropin | 12 | $530,456 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 25 | $8,938 |
| Prednisolone Acetate | 209 | $8,687 |
| CombiganBrimonidine Tartrate/Timolol | 25 | $6,281 |
| Fluorometholone | 47 | $4,746 |
| BromsiteBromfenac Sodium | 12 | $4,452 |
| Latanoprost | 325 | $3,281 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 27 | $3,139 |
| ValacyclovirValacyclovir Hcl | 25 | $2,845 |
| Cyclosporine | 13 | $2,819 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 168 | $2,525 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 16 | $1,661 |
| Difluprednate | 14 | $1,304 |
| Brimonidine Tartrate | 75 | $1,231 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $200 | $907,70418 claims |
| Mallinckrodt Hospital Products Inc.Acthar | $799 | $530,45612 claims |
| AlconSimbrinza | $836 | $8,93825 claims |
| AbbVieCombigan | $173 | $6,28125 claims |
| Sun Pharmaceutical Industries Inc.Bromsite | $145 | $4,45212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 266 ophthalmology providers in Indiana.
Other ophthalmology in Elkhart
- Shamik BafnaLafayette$505K
- Kevin WaltzIndianapolis$199K
- Janet HummerIndianapolis$96K
- Francis PriceIndianapolis$67K
- Omar DukarEvansville$43K
- Gerald RoperBatesville$34K
- Dwight SilveraEvansville$28K
- Michael OrrIndianapolis$26K
- Matthew FengIndianapolis$22K
- John LindIndianapolis$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.